243 related articles for article (PubMed ID: 19798644)
41. Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.
Berger JR; Koralnik IJ
N Engl J Med; 2005 Jul; 353(4):414-6. PubMed ID: 15947082
[No Abstract] [Full Text] [Related]
42. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
Martin Mdel P; Cravens PD; Winger R; Kieseier BC; Cepok S; Eagar TN; Zamvil SS; Weber MS; Frohman EM; Kleinschmidt-Demasters BK; Montine TJ; Hemmer B; Marra CM; Stüve O
Arch Neurol; 2009 Aug; 66(8):1016-20. PubMed ID: 19667224
[TBL] [Abstract][Full Text] [Related]
43. Tysabri withdrawal calls entire class into question.
Singer E
Nat Med; 2005 Apr; 11(4):359. PubMed ID: 15812500
[No Abstract] [Full Text] [Related]
44. The effects of natalizumab on the innate and adaptive immune system in the central nervous system.
Stüve O
J Neurol Sci; 2008 Nov; 274(1-2):39-41. PubMed ID: 18474372
[TBL] [Abstract][Full Text] [Related]
45. PML: underdiagnosed in MS patients on natalizumab.
Steiner I
Lancet Neurol; 2010 Jun; 9(6):564; author reply 564-5. PubMed ID: 20494319
[No Abstract] [Full Text] [Related]
46. Interruption of natalizumab therapy for multiple sclerosis: what are the risks?
Naismith RT; Bourdette D
Neurology; 2011 May; 76(22):1854-5. PubMed ID: 21543735
[No Abstract] [Full Text] [Related]
47. Progressive multifocal leukoencephalopathy after rituximab in a case of non-Hodgkin lymphoma.
Kranick SM; Mowry EM; Rosenfeld MR
Neurology; 2007 Aug; 69(7):704-6. PubMed ID: 17698796
[No Abstract] [Full Text] [Related]
48. Tysabri risk causing headache for companies.
Sheridan C
Nat Rev Drug Discov; 2005 Sep; 4(9):703-4. PubMed ID: 16178114
[No Abstract] [Full Text] [Related]
49. Rituximab in relapsing-remitting multiple sclerosis.
Schrijver HM
N Engl J Med; 2008 Jun; 358(24):2645; author reply 2646-7. PubMed ID: 18557177
[No Abstract] [Full Text] [Related]
50. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab.
Steinman L
Nat Rev Drug Discov; 2005 Jun; 4(6):510-8. PubMed ID: 15931259
[TBL] [Abstract][Full Text] [Related]
51. "Thinking without thinking" about natalizumab and PML.
Ransohoff RM
J Neurol Sci; 2007 Aug; 259(1-2):50-2. PubMed ID: 17521672
[TBL] [Abstract][Full Text] [Related]
52. Early relapses after the first dose of natalizumab in active multiple sclerosis patients.
Centonze D; Furlan R; Gasperini C; Salvetti M; Battistini L
Mult Scler; 2008 Sep; 14(8):1137-8. PubMed ID: 18701574
[TBL] [Abstract][Full Text] [Related]
53. Multiple sclerosis and Natalizumab.
Fiore D
Am J Ther; 2007; 14(6):555-60. PubMed ID: 18090880
[TBL] [Abstract][Full Text] [Related]
54. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Goodin DS; Cohen BA; O'Connor P; Kappos L; Stevens JC;
Neurology; 2008 Sep; 71(10):766-73. PubMed ID: 18765653
[TBL] [Abstract][Full Text] [Related]
55. Quantitative risk-benefit analysis of natalizumab.
Steiner I
Neurology; 2009 May; 72(20):1791-2; author reply 1791-2. PubMed ID: 19451538
[No Abstract] [Full Text] [Related]
56. How Tysabri survived.
Huggett B
Nat Biotechnol; 2009 Nov; 27(11):986. PubMed ID: 19898447
[TBL] [Abstract][Full Text] [Related]
57. 'Natalizumab in paediatric multiple sclerosis and service implication'.
Appleton RE; Boggild M
Dev Med Child Neurol; 2009 Sep; 51(9):758-9. PubMed ID: 19549194
[No Abstract] [Full Text] [Related]
58. Tysabri's return draws cautious optimism. Pharmacies, infusion centers must register to participate.
Traynor K
Am J Health Syst Pharm; 2006 Aug; 63(15):1388, 1392. PubMed ID: 16849700
[No Abstract] [Full Text] [Related]
59. Natalizumab and immune cells.
McFarland HF; Jacobson S
Arch Neurol; 2006 Oct; 63(10):1366-7. PubMed ID: 17030649
[No Abstract] [Full Text] [Related]
60. [Monoclonal antibodies improve therapy of relapsing multiple sclerosis. Molecular basis and clinical results of anti-VLA4 (natalizumab) therapy].
Gold R; Hartung HP; Hohlfeld R
Dtsch Med Wochenschr; 2006 Jan; 131(1-2):31-4. PubMed ID: 16374741
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
